Shire Plc said it will acquire NPS Pharmaceuticals Inc in an all-stock transaction for about $5.2 billion, the companies said in a joint statement on Sunday.Shire will pay $46.00 per NPS share, representing a premium of about 9.8 percent over NPS' Friday close.Dublin-based Shire, whose proposed sale to AbbVie Inc fell apart in October, expects the deal to add to its adjusted earnings from 2016 onward.
AbbVie Inc. (AbbVie) is a global research-based pharmaceuticals company. Shares of ABBV fell by 2.74% or $-1.85/share to $65.78. In the past year, the shares have traded as low as $45.50 and as high as $70.76. On average, 11445400 shares of ABBV exchange hands on a given day and today's volume is recorded at 8779934.
NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. Shares of NPSP fell by 2.35% or $-1.01/share to $41.91. In the past year, the shares have traded as low as $22.11 and as high as $42.95. On average, 1585980 shares of NPSP exchange hands on a given day and today's volume is recorded at 1091052.
Shire plc (Shire) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shares of SHPG traded higher by 1.59% or $3.4/share to $217.49. In the past year, the shares have traded as low as $141.32 and as high as $264.98. On average, 1904920 shares of SHPG exchange hands on a given day and today's volume is recorded at 1044116.
Source
